NASDAQ:ADIL Adial Pharmaceuticals (ADIL) Stock Price, News & Analysis $2.80 0.00 (0.00%) Closing price 07/17/2026 04:00 PM EasternExtended Trading$2.79 -0.01 (-0.39%) As of 08:45 AM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Massive. Learn more. Add Compare Share Share Stock Analysis Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFDA EventsHeadlinesInsider TradesOwnershipSEC FilingsTrendsBuy This Stock About Adial Pharmaceuticals Stock (NASDAQ:ADIL) View Price History Chart DataSkip Price History Chart 1 Day 5 Days 30 Days 90 Days 1 Year Advanced 1 Day 1 Day 5 Days 30 Days 90 Days 1 Year Advanced Show volume Show extended hours Get Adial Pharmaceuticals alerts:Sign Up Key Stats Today's Range$2.70▼$2.9050-Day Range$1.36▼$2.9852-Week Range$1.31▼$18.90Volume34,719 shsAverage Volume53,714 shsMarket Capitalization$5.99 millionP/E RatioN/ADividend YieldN/APrice Target$17.17Consensus RatingHold Company Overview Adial Pharmaceuticals, Inc., incorporated in Delaware and founded in 2003, is a clinical-stage specialty pharmaceutical company dedicated to the development of treatments for addiction disorders and central nervous system conditions. The company’s mission centers on creating novel modalities designed to enhance patient adherence and clinical outcomes, particularly in areas of high unmet medical need. Adial leverages sustained-release delivery technologies to address the challenges associated with oral medication regimens in addiction therapy. The company’s lead product candidate, AD04, is a bioerodible subcutaneous implant engineered to deliver naltrexone continuously over a multi-month period for individuals with alcohol dependence. This extended-release formulation aims to improve compliance and reduce relapse rates by maintaining therapeutic drug levels without the need for daily dosing. In addition to AD04, Adial is evaluating next-generation implant platforms and potential adjunctive therapies for substance use disorders, seeking to broaden its pipeline through strategic collaborations and in-house research efforts. Adial conducts clinical research primarily in North America, with previous trials extending to select international sites to gather comprehensive safety and efficacy data supporting future regulatory filings. The company operates through partnerships with academic institutions, contract research organizations and specialized clinical investigators to advance its development programs. Led by an executive team with extensive experience in pharmaceutical development, regulatory affairs and commercialization, Adial Pharmaceuticals continues to focus on addressing global challenges in addiction medicine and preparing for regulatory submissions that could pave the way for market entry.AI Generated. May Contain Errors. Read More Adial Pharmaceuticals Stock Analysis - MarketRank™See Top-Rated MarketRank™ Stocks83rd Percentile Overall ScoreADIL MarketRank™: Adial Pharmaceuticals scored higher than 83% of companies evaluated by MarketBeat. Scores are calculated by averaging available category scores, with extra weight given to analysis and valuation. Analyst's Opinion3.7 / 5Analyst RatingHold Consensus RatingAdial Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.20, and is based on no strong buy ratings, 2 buy ratings, 2 hold ratings, and 1 sell rating.Upside PotentialAdial Pharmaceuticals has a consensus price target of $17.17, representing about 513.1% upside from its current price of $2.80.Amount of Analyst CoverageAdial Pharmaceuticals has only been the subject of 3 research reports in the past 90 days.Read more about Adial Pharmaceuticals' stock forecast and price target. Earnings and Valuation0.6 / 5Proj. Earnings GrowthN/A Price to Earnings Ratio vs. the MarketThe P/E ratio of Adial Pharmaceuticals is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Adial Pharmaceuticals is -0.35, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAdial Pharmaceuticals has a P/B Ratio of 0.59. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Adial Pharmaceuticals' valuation and earnings. Short Interest4.0 / 5Short Interest LevelHealthy Percentage of Shares Shorted10.98% of the float of Adial Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAdial Pharmaceuticals has a short interest ratio ("days to cover") of 1.81, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Adial Pharmaceuticals has recently decreased by 33.46%, indicating that investor sentiment is improving significantly. Dividend0.0 / 5Dividend StrengthN/A Dividend YieldAdial Pharmaceuticals does not currently pay a dividend.Dividend GrowthAdial Pharmaceuticals does not have a long track record of dividend growth. News and Social Media3.8 / 5News Sentiment1.15 News SentimentAdial Pharmaceuticals has a news sentiment score of 1.15. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.68 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 4 news articles for Adial Pharmaceuticals this week, compared to 3 articles on an average week.Search Interest6 people have searched for ADIL on MarketBeat in the last 30 days. This is an increase of 200% compared to the previous 30 days.MarketBeat FollowsOnly 1 people have added Adial Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is a decrease of 0% compared to the previous 30 days. Company Ownership3.1 / 5Insider TradingAcquiring Shares Net Insider BuyingOver the last three months, insiders have purchased a net $97,638.00 in company stock, which represents 1.6295% of the company's market cap.Insider Buying vs. Insider SellingIn the past three months, Adial Pharmaceuticals insiders have bought more of their company's stock than they have sold. Specifically, they have bought $97,638.00 in company stock and sold $0.00 in company stock.Percentage Held by Insiders1.86% of the stock of Adial Pharmaceuticals is held by insiders.Percentage Held by Institutions16.41% of the stock of Adial Pharmaceuticals is held by institutions.Read more about Adial Pharmaceuticals' insider trading history. Receive ADIL Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Adial Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Submit View SMS TermsSMS is currently available in Australia, Belgium, Canada, France, Germany, Ireland, Italy, New Zealand, the Netherlands, Singapore, South Africa, Spain, Switzerland, the United Kingdom, and the United States. By entering your phone number and clicking the sign-up button, you agree to receive periodic text messages from MarketBeat at the phone number you submitted, including texts that may be sent using an automatic telephone dialing system. Message and data rates may apply. Message frequency will vary. Messages will consist of stock alerts, news stories, and partner advertisements/offers. Consent is not a condition of the purchase of any goods or services. Text HELP for help/customer support. Unsubscribe at any time by replying "STOP" to any text message that you receive from MarketBeat or by visiting our mailing preferences page. Read our full terms of service and privacy policy. ADIL Stock News HeadlinesCoastlands Capital Lp Purchases 10,053 Shares of Adial Pharmaceuticals (NASDAQ:ADIL) StockJuly 15, 2026 | americanbankingnews.comAdial Pharmaceuticals (NASDAQ:ADIL) Major Shareholder Coastlands Capital Lp Purchases 10,053 SharesJuly 14, 2026 | insidertrades.comNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried to acquire it outright for $40 billion - the White House blocked the deal on national security grounds. So NVIDIA settled for a 20-year supply deal instead. Its architecture delivers '2-3x performance per watt' by NVIDIA's own admission, and its data-center royalties more than doubled last quarter. Analyst Dylan Jovine - who called Palantir at $7.38 and Rocket Lab at $3.80 - has named it his number-one pick ahead of its July 29th earnings report.July 20 at 1:00 AM | Behind the Markets (Ad)Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) Given Average Recommendation of "Hold" by BrokeragesJuly 10, 2026 | americanbankingnews.comCoastlands Capital Lp Acquires 25,000 Shares of Adial Pharmaceuticals (NASDAQ:ADIL) StockJuly 2, 2026 | insidertrades.comAdial Pharmaceuticals Expands Executive Leadership Team and Closes PIPE FinancingJune 16, 2026 | globenewswire.comADIL Stock Eyes Best Day In Over 5 Years — Major Pipeline Overhaul And $64M Raise Fuel RallyJune 11, 2026 | msn.comAdial Pharmaceuticals Acquires Azora Therapeutics to Advance Development of Novel Ulcerative Colitis Treatment AT177June 11, 2026 | quiverquant.comQSee More Headlines ADIL Stock Analysis - Frequently Asked Questions How have ADIL shares performed this year? Adial Pharmaceuticals' stock was trading at $5.50 at the start of the year. Since then, ADIL stock has decreased by 49.1% and is now trading at $2.80. How were Adial Pharmaceuticals' earnings last quarter? Adial Pharmaceuticals, Inc. (NASDAQ:ADIL) released its quarterly earnings data on Friday, May, 8th. The company reported ($1.48) EPS for the quarter, topping analysts' consensus estimates of ($2.73) by $1.25. When did Adial Pharmaceuticals' stock split? Adial Pharmaceuticals's stock reverse split on Friday, February 6th 2026.The 1-25 reverse split was announced on Tuesday, February 3rd 2026. The number of shares owned by shareholders was adjusted after the closing bell on Thursday, February 5th 2026. An investor that had 100 shares of stock prior to the reverse split would have 4 shares after the split. When did Adial Pharmaceuticals IPO? Adial Pharmaceuticals (ADIL) raised $15 million in an IPO on Friday, July 27th 2018. The company issued 1,464,000 shares at $9.00-$11.00 per share. Joseph Gunnar & Co. served as the underwriter for the IPO and Dawson James Securities was co-manager. How do I buy shares of Adial Pharmaceuticals? Shares of ADIL stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. What other stocks do shareholders of Adial Pharmaceuticals own? Based on aggregate information from My MarketBeat watchlists, some other companies that Adial Pharmaceuticals investors own include NVIDIA (NVDA), Adobe (ADBE), Broadcom (AVGO), CrowdStrike (CRWD), Arista Networks (ANET) and GE Aerospace (GE). Company Calendar Last Earnings5/08/2026Today7/20/2026Next Earnings (Estimated)8/12/2026Fiscal Year End12/31/2026Get Stock Alerts Health Indicator TradeSmith's Health IndicatorA long-term volatility-based measure designed for securities held 12 months or longer.Green: Strong and healthy uptrend with normal pullbacks.Yellow: Significant pullback but still within expected volatility.Red: Dropped beyond expected volatility; considered unhealthy. Green Zone (1m+) 1-Year History Jul 25 Oct 25 Jan 26 Apr 26 Jul 26 ADIL's financial health is in the Green zone, according to TradeSmith. ADIL has been in this zone for over one month. Industry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Biotechnology Sub-IndustryPharmaceutical Products Current SymbolNASDAQ:ADIL CIK1513525 Webwww.adialpharma.com Phone(434) 422-9800FaxN/AEmployees20Year Founded2010Price Target and Rating Average Price Target for Adial Pharmaceuticals$17.17 High Price Target$37.50 Low Price Target$6.00 Potential Upside/Downside+513.1%Consensus RatingHold Rating Score (0-4)2.20 Research Coverage5 Analysts Profitability EPS (Trailing Twelve Months)($7.98) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income-$7.98 million Net MarginsN/A Pretax MarginN/A Return on Equity-162.82% Return on Assets-127.58% Debt Debt-to-Equity RatioN/A Current Ratio3.18 Quick Ratio3.18 Sales & Book Value Annual SalesN/A Price / SalesN/A Cash FlowN/A Price / Cash FlowN/A Book Value$4.75 per share Price / Book0.59Miscellaneous Outstanding Shares2,140,000Free Float2,104,000Market Cap$5.99 million OptionableNo Data Beta1.43 Social Links 7 Stocks That Could Lead the Next Market BoomTesla, Nvidia, and Google helped shape the last era of market growth, but the next wave could come from a new group of companies. Inside this report, you’ll find 7 stocks that could play a major role in the next tech-driven market boom.Get This Free Report This page (NASDAQ:ADIL) was last updated on 7/20/2026 by MarketBeat.com Staff. From Our PartnersNVIDIA offered $40B. The answer was no.Apple, NVIDIA, Google, Amazon, and Samsung all pay one company billions in royalties every year. NVIDIA tried ...Behind the Markets | SponsoredBuy this stock tomorrowMarc Chaikin, founder of Chaikin Analytics, is flagging a little-known company that just secured a partnership...Chaikin Analytics | SponsoredThe gold strategy buried in Trump's plans that insiders are already watchingNancy Pelosi's portfolio gained 71 percent in 2024 while the S&P 500 returned just 28 percent. In 2023, she ea...American Alternative | SponsoredMy next big call (under $1)17,556% on KDA. Here's what I'm buying now. It's a coin under $1.00 that most investors have never heard of...Crypto 101 Media | SponsoredTrump’s $250 Bill – See ImmediatelyFormer Goldman Sachs VP Dr. David Eifrig is warning that July 28 could trigger the biggest wealth reset in mod...Stansberry Research | SponsoredThe chipmaker 148 times smaller than NVIDIA supplying MuskAccording to Yahoo Finance, Elon Musk's latest project could 'upend another industry just as he did with cars ...Brownstone Research | SponsoredGold Is About to Do Something It Hasn’t in 90 YearsThe U.S. Treasury still carries America's gold reserves at $42 per ounce — a price set generations ago. Buried...US Gold Bureau | SponsoredNEW LAW: Congress Approves Setup For Digital Dollar?On July 17th, the House passed the GENIUS Act - and at least one prominent Trump ally is raising alarms. Rep. ...Goldco Direct, LLC | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added ten stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Adial Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Adial Pharmaceuticals With A Colleague Link copied to clipboard. Unlock superior investment research and tools. Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools and reports. Get MarketBeat All Access MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In Email Me a Login Link or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
